{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:06:10Z","timestamp":1791511570283,"version":"4.3.4"},"reference-count":141,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Melanoma and nonmelanoma skin cancers (NMSCs) are recognized as among the most common neoplasms, mostly in white people, with an increasing incidence rate. Among the NMSCs, squamous cell carcinoma (SCC) is the most prevalent malignancy known to affect people with a fair complexion who are exposed to extreme ultraviolet radiation (UVR), have a hereditary predisposition, or are immunosuppressed. There are several extrinsic and intrinsic determinants that contribute to the pathophysiology of the SCC. The therapeutic modalities depend on the SCC stages, from actinic keratosis to late-stage multiple metastases. Standard treatments include surgical excision, radiotherapy, and chemotherapy. As SCC represents a favorable tumor microenvironment with high tumor mutational burden, infiltration of immune cells, and expression of immune checkpoints, the SCC tumors are highly responsive to immunotherapies. Until now, there are three checkpoint inhibitors, cemiplimab, pembrolizumab, and nivolumab, that are approved for the treatment of advanced, recurrent, or metastatic SCC patients in the United States. Immunotherapy possesses significant therapeutic benefits for patients with metastatic or locally advanced tumors not eligible for surgery or radiotherapy to avoid the potential toxicity caused by the chemotherapies. Despite the high tolerability and efficiency, the existence of some challenges has been revealed such as, resistance to immunotherapy, less availability of the biomarkers, and difficulty in appropriate patient selection. This review aims to accumulate evidence regarding the genetic alterations related to SCC, the factors that contribute to the potential benefits of immunotherapy, and the challenges to follow this treatment regime.<\/jats:p>","DOI":"10.3390\/ijms23158530","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T21:01:24Z","timestamp":1659387684000},"page":"8530","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges"],"prefix":"10.3390","volume":"23","author":[{"given":"Tuba M.","family":"Ansary","sequence":"first","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MD Razib","family":"Hossain","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1086-1803","authenticated-orcid":false,"given":"Mayumi","family":"Komine","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"ref_1","first-page":"120","article-title":"Epidemiology of skin cancer","volume":"810","author":"Leiter","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaad.2005.08.063","article-title":"Skin cancer in skin of color","volume":"55","author":"Gloster","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","unstructured":"Ward, W.H., and Farma, J.M. (2017). The Epidemiology of Cutaneous Melanoma in the White and Black African Population Groups in South Africa. Cutaneous Melanoma: Etiology and Therapy, Codon Publications."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fania, L., Didona, D., Di Pietro, F.R., Verkhovskaia, S., Morese, R., Paolino, G., Donati, M., Ricci, F., Coco, V., and Ricci, F. (2021). Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 9.","DOI":"10.3390\/biomedicines9020171"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"866733","DOI":"10.3389\/fonc.2022.866733","article-title":"Ozone Layer Depletion and Emerging Public Health Concerns\u2014An Update on Epidemiological Perspective of the Ambivalent Effects of Ultraviolet Radiation Exposure","volume":"12","author":"Umar","year":"2022","journal-title":"Front. Oncol"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_7","unstructured":"Xu, Y.G., Aylward, J.L., Swanson, A.M., Spiegelman, V.S., Vanness, E.R., Teng, J.M., Snow, S.N., and Wood, G.S. (2013). Nonmelanoma Skin Cancers: Basal Cell and Squamous Cell Carcinomas, Elsevier Inc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1038\/s41598-021-83502-8","article-title":"The incidence and clinical analysis of non-melanoma skin cancer","volume":"11","author":"Ciazynska","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2020.2571","article-title":"Association of Age, Sex, Race, and Geographic Region With Variation of the Ratio of Basal Cell to Cutaneous Squamous Cell Carcinomas in the United States","volume":"156","author":"Lukowiak","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrc2089","article-title":"Tumour microenvironment: Laminin 332 in squamous-cell carcinoma","volume":"7","author":"Marinkovich","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1200\/JCO.2005.02.155","article-title":"Mortality risk from squamous cell skin cancer","volume":"23","author":"Clayman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/DSS.0000000000002117","article-title":"Characteristics of Patients Hospitalized for Cutaneous Squamous Cell Carcinoma","volume":"46","author":"Tripathi","year":"2020","journal-title":"Dermatol. Surg."},{"key":"ref_13","unstructured":"American Cancer Society (2022, June 12). Key Statistics for Basal and Squamous Cell Skin Cancers. Available online: https:\/\/www.cancer.org\/cancer\/basal-and-squamous-cell-skin-cancer\/about\/key-statistics.html#:~:text=Death%20from%20basal%20and%20squamous,been%20dropping%20in%20recent%20years."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1440-0960.1996.tb00990.x","article-title":"Deaths due to squamous cell carcinoma in Australia: Is there a case for a public health intervention?","volume":"37","author":"Rosenblatt","year":"1996","journal-title":"Australas. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/jamadermatol.2020.1988","article-title":"Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) In situ Incidence and the Risk of Developing Invasive cSCC in Patients With Prior cSCC In situ vs the General Population in the Netherlands, 1989\u20132017","volume":"156","author":"Tokez","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2018.08.001","article-title":"Cutaneous Squamous Cell Carcinoma","volume":"33","author":"Waldman","year":"2019","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_17","first-page":"275","article-title":"Squamous Cell Carcinoma\u2014Similarities and Differences among Anatomical Sites","volume":"1","author":"Yan","year":"2011","journal-title":"Am. J. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"727027","DOI":"10.3389\/fonc.2021.727027","article-title":"Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives","volume":"11","author":"Alberti","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ijd.12553","article-title":"Squamous cell carcinoma of the skin: Epidemiology, classification, management, and novel trends","volume":"54","author":"Kallini","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/17512433.2019.1665026","article-title":"Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma","volume":"12","author":"Ahmed","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-9255-9-46","article-title":"Inflammatory events during murine squamous cell carcinoma development","volume":"9","author":"Gasparoto","year":"2012","journal-title":"J. Inflamm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s10147-020-01829-0","article-title":"Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: A multicenter retrospective clinical study","volume":"26","author":"Hanai","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ccell.2016.04.004","article-title":"Squamous Cell Cancers: A Unified Perspective on Biology and Genetics","volume":"29","author":"Dotto","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1758-3284-4-8","article-title":"Primary squamous cell carcinoma of thyroid: A case report and review of literature","volume":"4","author":"Tunio","year":"2012","journal-title":"Head Neck Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1177\/000313480907501010","article-title":"Squamous cell carcinoma of the breast: A review of 177 cases","volume":"75","author":"Grabowski","year":"2009","journal-title":"Am. Surg."},{"key":"ref_26","first-page":"56","article-title":"Squamous cell carcinoma of the prostate","volume":"13","author":"Malik","year":"2011","journal-title":"Rev. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e12596","DOI":"10.1097\/MD.0000000000012596","article-title":"An unusual location of squamous cell carcinoma and a rare cutaneous infection caused by serratia marcescens on the tumoral tissue: A case report","volume":"97","author":"Sevencan","year":"2018","journal-title":"Medicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/phpp.12139","article-title":"The relationship between UV exposure and incidence of skin cancer","volume":"31","author":"Moan","year":"2015","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1524-4725.1996.tb00315.x","article-title":"The many faces of squamous cell carcinoma","volume":"22","author":"Bernstein","year":"1996","journal-title":"Dermatol. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jaad.2015.08.073","article-title":"Familial skin cancer syndromes: Increased risk of nonmelanotic skin cancers and extracutaneous tumors","volume":"74","author":"Jaju","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Axibal, E.L., and Brown, M.R. (2018). Squamous Cell Carcinoma, Springer.","DOI":"10.1007\/978-3-319-74903-7_4"},{"key":"ref_32","first-page":"E32","article-title":"Systemic medications linked to an increased risk for skin malignancy","volume":"104","author":"Johnson","year":"2019","journal-title":"Cutis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jdv.12921","article-title":"Use of antihypertensive drugs and risk of skin cancer","volume":"29","author":"Schmidt","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/archderm.136.8.1007","article-title":"Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group","volume":"136","author":"Lichter","year":"2000","journal-title":"Arch. Dermatol."},{"key":"ref_35","first-page":"419","article-title":"Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin","volume":"5","author":"Gallagher","year":"1996","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_36","first-page":"85","article-title":"Incidence of etiologic factors in squamous cell carcinoma of head and neck in ahvaz","volume":"24","author":"Nikakhlagh","year":"2012","journal-title":"Iran. J. Otorhinolaryngol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jaad.2011.04.004","article-title":"The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: A 30-year prospective study","volume":"66","author":"Stern","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/archderm.1995.01690140048007","article-title":"Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer. II. Squamous cell carcinoma","volume":"131","author":"Gallagher","year":"1995","journal-title":"Arch. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00129334-200301000-00014","article-title":"Wounds and malignancy","volume":"16","author":"Trent","year":"2003","journal-title":"Adv. Skin Wound Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1001\/jama.1992.03480240067036","article-title":"Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group","volume":"267","author":"Karagas","year":"1992","journal-title":"JAMA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/cid\/cit940","article-title":"Voriconazole-associated cutaneous malignancy: A literature review on photocarcinogenesis in organ transplant recipients","volume":"58","author":"Williams","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.146.s61.2.x","article-title":"The epidemiology of skin cancer","volume":"146","author":"Diepgen","year":"2002","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.gendis.2014.08.005","article-title":"Ultraviolet radiation-induced non-melanoma skin cancer: Regulation of DNA damage repair and inflammation","volume":"1","author":"Kim","year":"2014","journal-title":"Genes Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cosmetics5010016","article-title":"Equol\u2019s Anti-Aging Effects Protect against Environmental Assaults by Increasing Skin Antioxidant Defense and ECM Proteins While Decreasing Oxidative Stress and Inflammation","volume":"5","author":"Lephart","year":"2018","journal-title":"Cosmetics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/ced.14456","article-title":"Shedding light on the myths of ultraviolet radiation in the COVID-19 pandemic","volume":"46","author":"Courtney","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3390\/genes11121450","article-title":"The Dark Side of UV-Induced DNA Lesion Repair","volume":"11","author":"Kowalska","year":"2020","journal-title":"Genes"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"13538","DOI":"10.1073\/pnas.0504497102","article-title":"UVA radiation is highly mutagenic in cells that are unable to repair 7,8-dihydro-8-oxoguanine in Saccharomyces cerevisiae","volume":"102","author":"Kozmin","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"160","DOI":"10.17533\/udea.iatreia.v30n2a05","article-title":"Mechanisms of skin aging","volume":"30","author":"Sanclemente","year":"2017","journal-title":"Iatreia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"11808","DOI":"10.1038\/srep11808","article-title":"Detection of UV-induced cyclobutane pyrimidine dimers by near-infrared spectroscopy and aquaphotomics","volume":"5","author":"Goto","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10124","DOI":"10.1073\/pnas.88.22.10124","article-title":"A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma","volume":"88","author":"Brash","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","first-page":"136","article-title":"Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion","volume":"1","author":"Brash","year":"1996","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1523-1747.1998.00090.x","article-title":"Induction of squamous cell carcinoma in p53-deficient mice after ultraviolet irradiation","volume":"110","author":"Li","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.1038\/sj.onc.1208863","article-title":"Fate of UVB-induced p53 mutations in SKH-hr1 mouse skin after discontinuation of irradiation: Relationship to skin cancer development","volume":"24","author":"Melnikova","year":"2005","journal-title":"Oncogene"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3389\/fonc.2020.01460","article-title":"Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy","volume":"10","author":"Chasov","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12255","DOI":"10.1073\/pnas.94.23.12255","article-title":"p53-mediated protective responses to UV irradiation","volume":"94","author":"Smith","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/372773a0","article-title":"Sunburn and p53 in the onset of skin cancer","volume":"372","author":"Ziegler","year":"1994","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/s41467-018-06027-1","article-title":"The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature","volume":"9","author":"Inman","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.0022-202X.2004.22501.x","article-title":"p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma","volume":"122","author":"Brown","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1038\/sj.onc.1202915","article-title":"P16 UV mutations in human skin epithelial tumors","volume":"18","author":"Soufir","year":"1999","journal-title":"Oncogene"},{"key":"ref_60","first-page":"518","article-title":"P16 is overexpressed in cutaneous carcinomas located on sun-exposed areas","volume":"16","author":"Conscience","year":"2006","journal-title":"Eur. J. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/01.MP.0000032536.48264.D1","article-title":"Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin","volume":"15","author":"Hodges","year":"2002","journal-title":"Mod. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1600-0560.1995.tb00758.x","article-title":"Cyclin D and retinoblastoma gene product expression in actinic keratosis and cutaneous squamous cell carcinoma in relation to p53 expression","volume":"22","author":"Bito","year":"1995","journal-title":"J. Cutan. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/jid.2014.163","article-title":"TERT promoter mutations in skin cancer: The effects of sun exposure and X-irradiation","volume":"134","author":"Populo","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/modpathol.2013.167","article-title":"Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma","volume":"27","author":"Scott","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00204-008-0313-y","article-title":"Carcinogenic metal compounds: Recent insight into molecular and cellular mechanisms","volume":"82","author":"Beyersmann","year":"2008","journal-title":"Arch. Toxicol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s11373-006-9092-8","article-title":"Arsenic carcinogenesis in the skin","volume":"13","author":"Yu","year":"2006","journal-title":"J. Biomed. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1523-1747.1999.00630.x","article-title":"The role of oxidative DNA damage in human arsenic carcinogenesis: Detection of 8-hydroxy-2\u2032-deoxyguanosine in arsenic-related Bowen\u2019s disease","volume":"113","author":"Matsui","year":"1999","journal-title":"J. Investig. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/toxsci\/kfj030","article-title":"DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy","volume":"89","author":"Chanda","year":"2006","journal-title":"Toxicol. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Huang, H.W., Lee, C.H., and Yu, H.S. (2019). Arsenic-Induced Carcinogenesis and Immune Dysregulation. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16152746"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.taap.2004.01.006","article-title":"Exposure to chromium (VI) in the drinking water increases susceptibility to UV-induced skin tumors in hairless mice","volume":"196","author":"Davidson","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_71","first-page":"939","article-title":"Smoking and the risk of nonmelanoma skin cancer: Systematic review and meta-analysis","volume":"148","author":"Ellison","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.1206923","article-title":"Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1","volume":"333","author":"Agrawal","year":"2011","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.18332\/tid\/111652","article-title":"Tobacco and oral squamous cell carcinoma: A review of carcinogenic pathways","volume":"17","author":"Jiang","year":"2019","journal-title":"Tob. Induc. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/1523-1747.ep12319764","article-title":"p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA)","volume":"109","author":"Nataraj","year":"1997","journal-title":"J. Investig. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"King, A.J., Arnone, M.R., Bleam, M.R., Moss, K.G., Yang, J., Fedorowicz, K.E., Smitheman, K.N., Erhardt, J.A., Hughes-Earle, A., and Kane-Carson, L.S. (2013). Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF\/MEK tool combination reduced skin lesions. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0067583"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamadermatol.2014.583","article-title":"Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: Cases illustrating the importance of serial biopsy during vismodegib usage","volume":"150","author":"Zhu","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma","volume":"152","author":"Mohan","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","article-title":"A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis","volume":"86","author":"Lin","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5021\/ad.2019.31.2.204","article-title":"Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib","volume":"31","author":"Bellosillo","year":"2019","journal-title":"Ann. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"247","DOI":"10.14740\/jocmr3744","article-title":"Association Between the Use of Thiazide Diuretics and the Risk of Skin Cancers: A Meta-Analysis of Observational Studies","volume":"11","author":"Shin","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jamadermatol.2020.1141","article-title":"Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States","volume":"156","author":"Pfeiffer","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jamadermatol.2018.4406","article-title":"Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients","volume":"155","author":"Lanz","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_86","first-page":"1","article-title":"Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma","volume":"3","author":"Roudiani","year":"2018","journal-title":"JCI Insight"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1365-2133.2005.06447.x","article-title":"Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds","volume":"152","author":"Impola","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Filoni, A., Cicco, G., Cazzato, G., Bosco, A., Lospalluti, L., Tucci, M., Cimmino, A., Foti, C., Marzullo, A., and Bonamonte, D. (2022). Immune Disregulation in Cutaneous Squamous Cell Carcinoma of Patients with Recessive Dystrophic Epidermolysis Bullosa: A Single Pilot Study. Life, 12.","DOI":"10.3390\/life12020213"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Condorelli, A.G., Dellambra, E., Logli, E., Zambruno, G., and Castiglia, D. (2019). Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225707"},{"key":"ref_90","first-page":"885","article-title":"Metastatic cutaneous squamous cell carcinoma: An update","volume":"33","author":"Weinberg","year":"2007","journal-title":"Dermatol. Surg."},{"key":"ref_91","first-page":"201","article-title":"Progression of actinic keratosis to squamous cell carcinoma revisited: Clinical and treatment implications","volume":"87","author":"Feldman","year":"2011","journal-title":"Cutis"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e399","DOI":"10.3747\/co.27.6015","article-title":"Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"27","author":"Claveau","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1586\/14737140.2015.1042865","article-title":"Radiotherapy treatment for nonmelanoma skin cancer","volume":"15","author":"Rong","year":"2015","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00000421-200004000-00015","article-title":"Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged","volume":"23","author":"Cartei","year":"2000","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12957-018-1425-3","article-title":"Immunohistochemical expression of epidermal growth factor receptor (EGFR) in South Asian head and neck squamous cell carcinoma: Association with various risk factors and clinico-pathologic and prognostic parameters","volume":"16","author":"Hashmi","year":"2018","journal-title":"World J. Surg. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"105815","DOI":"10.1016\/j.oraloncology.2022.105815","article-title":"Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048","volume":"128","author":"Rischin","year":"2022","journal-title":"Oral. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18632\/oncotarget.27434","article-title":"Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre study","volume":"11","author":"Montaudie","year":"2020","journal-title":"Oncotarget"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2017.07.048","article-title":"Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial","volume":"77","author":"William","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): An open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41575-022-00615-9","article-title":"Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma","volume":"19","author":"Hindson","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/CCO.0000000000000566","article-title":"Advanced cutaneous squamous cell carcinoma: How is it defined and what new therapeutic approaches are available?","volume":"31","author":"Soura","year":"2019","journal-title":"Curr. Opin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12935-021-02024-5","article-title":"A review on the advances and challenges of immunotherapy for head and neck cancer","volume":"21","author":"Cheng","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"9526","DOI":"10.1200\/JCO.2019.37.15_suppl.9526","article-title":"Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC.; Group 1): 12-month follow-up","volume":"37","author":"Guminski","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41392-020-00419-w","article-title":"Tumor microenvironment: An evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy","volume":"6","author":"Bhat","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Nisar, S., Yousuf, P., Masoodi, T., Wani, N.A., Hashem, S., Singh, M., Sageena, G., Mishra, D., Kumar, R., and Haris, M. (2021). Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094584"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-019-0983-5","article-title":"Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: A systematic review","volume":"18","author":"Peltanova","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3892\/mco.2022.2492","article-title":"Expression of PD-L1 and CD4+ tumor-infiltrating lymphocytes predict survival in head and neck squamous cell carcinoma","volume":"16","author":"Fu","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/PAI.0b013e31828df3c9","article-title":"Analysis of CD8+ and CD4+ cells in oral squamous cell carcinoma and their association with lymph node metastasis and histologic grade of malignancy","volume":"22","year":"2014","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Freeman, A., Bridge, J.A., Maruthayanar, P., Overgaard, N.H., Jung, J.W., Simpson, F., Prow, T.W., Soyer, H.P., Frazer, I.H., and Freeman, M. (2014). Comparative immune phenotypic analysis of cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in immune-competent individuals: Proportional representation of CD8+ T-cells but not FoxP3+ Regulatory T-cells is associated with disease stage. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0110928"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00262-004-0652-3","article-title":"Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system","volume":"54","author":"Weber","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40425-018-0493-9","article-title":"alpha-PD-1 therapy elevates Treg\/Th balance and increases tumor cell pSmad3 that are both targeted by alpha-TGFbeta antibody to promote durable rejection and immunity in squamous cell carcinomas","volume":"7","author":"Meyer","year":"2019","journal-title":"J. Immunother Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"756506","DOI":"10.3389\/fgene.2021.756506","article-title":"Combination of Tumor Mutational Burden and Specific Gene Mutations Stratifies Outcome to Immunotherapy Across Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma","volume":"12","author":"Peng","year":"2021","journal-title":"Front. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e223833","DOI":"10.1001\/jamanetworkopen.2022.3833","article-title":"Prevalence of UV Mutational Signatures Among Cutaneous Primary Tumors","volume":"5","author":"Mata","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"611115","DOI":"10.3389\/fonc.2021.611115","article-title":"The Role of Macrophages in Oral Squamous Cell Carcinoma","volume":"11","author":"Kalogirou","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pathol.2016.02.006","article-title":"Tumour-associated macrophages are recruited and differentiated in the neoplastic stroma of oral squamous cell carcinoma","volume":"48","author":"Essa","year":"2016","journal-title":"Pathology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/jid.2011.9","article-title":"Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated","volume":"131","author":"Pettersen","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.yexmp.2012.01.003","article-title":"Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma","volume":"92","author":"Roh","year":"2012","journal-title":"Exp. Mol. Pathol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13000-019-0778-4","article-title":"PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population","volume":"14","author":"Rong","year":"2019","journal-title":"Diagn. Pathol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGFbeta biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1111\/cas.15081","article-title":"Improving function of cytotoxic T-lymphocytes by transforming growth factor-beta inhibitor in oral squamous cell carcinoma","volume":"112","author":"Kondo","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Son, H.K., Kim, D., Lim, Y., Kim, J., and Park, I. (2020). A novel TGF-beta receptor II mutation (I227T\/N236D) promotes aggressive phenotype of oral squamous cell carcinoma via enhanced EGFR signaling. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07669-5"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"590912","DOI":"10.3389\/fmolb.2020.590912","article-title":"Roles of the Wnt Signaling Pathway in Head and Neck Squamous Cell Carcinoma","volume":"7","author":"Xie","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/2326-6066.CIR-18-0716","article-title":"Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness","volume":"7","author":"Goodman","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Burcher, K.M., Lantz, J.W., Gavrila, E., Abreu, A., Burcher, J.T., Faucheux, A.T., Xie, A., Jackson, C., Song, A.H., and Hughes, R.T. (2021). Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13225733"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1002\/cam4.1529","article-title":"Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1","volume":"7","author":"Zhang","year":"2018","journal-title":"Cancer Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance Mechanisms of Anti-PD1\/PDL1 Therapy in Solid Tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41586-018-0768-9","article-title":"Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade","volume":"565","author":"Ishizuka","year":"2019","journal-title":"Nature"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13000-017-0600-0","article-title":"ADAR1 overexpression is associated with cervical cancer progression and angiogenesis","volume":"12","author":"Chen","year":"2017","journal-title":"Diagn. Pathol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1586\/14737140.2014.928595","article-title":"ADAR1: A promising new biomarker for esophageal squamous cell carcinoma?","volume":"14","author":"Qiao","year":"2014","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.molcel.2021.01.010","article-title":"Interferon-gamma induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation","volume":"81","author":"Yu","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Ge, L., Smail, M., Meng, W., Shyr, Y., Ye, F., Fan, K.H., Li, X., Zhou, H.M., and Bhowmick, N.A. (2011). Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027529"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/15\/8530\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:41Z","timestamp":1760140841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/15\/8530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":141,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ijms23158530"],"URL":"https:\/\/doi.org\/10.3390\/ijms23158530","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}